Tumour Treating Fields for mesothelioma

Affiliations

¹ Department of Biotechnologies, University of Siena, Siena, Italy. Electronic address: marcella7573@hotmail.com.
² Department of Biotechnologies, University of Siena, Siena, Italy.
³ Department of Biotechnologies, University of Siena, Siena, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA.
⁴ Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA.

Comment

Marcella Barbarino et al. Lancet Oncol. 2020 Jan.

. 2020 Jan;21(1):e8.

doi: 10.1016/S1470-2045(19)30829-0.

¹ Department of Biotechnologies, University of Siena, Siena, Italy. Electronic address: marcella7573@hotmail.com.
² Department of Biotechnologies, University of Siena, Siena, Italy.
³ Department of Biotechnologies, University of Siena, Siena, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA.
⁴ Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, USA.

No abstract available

Comment in

Tumour Treating Fields for mesothelioma - Authors' reply.
Ceresoli GL, Gianoncelli L, Grosso F; STELLAR investigators. Ceresoli GL, et al. Lancet Oncol. 2020 Jan;21(1):e10. doi: 10.1016/S1470-2045(19)30831-9. Lancet Oncol. 2020. PMID: 31908296 No abstract available.

Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F. Ceresoli GL, et al. Lancet Oncol. 2019 Dec;20(12):1702-1709. doi: 10.1016/S1470-2045(19)30532-7. Epub 2019 Oct 15. Lancet Oncol. 2019. PMID: 31628016 Clinical Trial.